Skip to main navigation
Skip to search
Skip to main content
Sort by
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy Regimens
100%
Granulocyte Colony Stimulating Factor
84%
Malignant Neoplasm
45%
Abdominal Cancer
38%
Overall Survival
37%
Cisplatin
31%
Metastatic Colorectal Cancer
30%
Febrile Neutropenia
29%
Bevacizumab
29%
Progression Free Survival
28%
Colorectal Carcinoma
26%
Sulfasalazine
24%
Nivolumab
21%
Adverse Event
17%
Ramucirumab
15%
Doxorubicin
14%
Esophagus Cancer
14%
Soft Tissue Sarcoma
14%
Thrombocytopenia
14%
CD44v Antigen
14%
Lymphoproliferative Disease
14%
Acute Myeloid Leukemia
14%
Atrophic Gastritis
14%
Eribulin
14%
Pembrolizumab
14%
Breast Cancer
14%
Diseases
13%
Regorafenib
12%
Oxaliplatin
12%
Infection
12%
Neoplasm
11%
Non Small Cell Lung Cancer
10%
Tumor Growth
10%
Immune Deficiency
10%
Epstein-Barr Virus
10%
Platinum
9%
Randomized Controlled Trial
9%
Trifluridine
9%
Tipiracil
9%
Neutropenia
8%
Intestine Metaplasia
8%
Pazopanib
8%
Retrospective Study
8%
Neuroendocrine Carcinoma
8%
Head and Neck Cancer
8%
Pegfilgrastim
8%
Observational Study
8%
Carcinoma
8%
Carcinogenesis
7%
Fluorouracil
7%
Medicine and Dentistry
Chemotherapy
94%
Systematic Review
49%
Granulocyte Colony Stimulating Factor
49%
Overall Survival
39%
Retrospective Study
35%
Clinical Oncology
35%
Metastatic Colorectal Cancer
35%
Meta-Analysis
22%
Progression Free Survival
22%
Regorafenib
20%
Neuroendocrine Carcinoma
18%
Genetics
18%
Organoid
17%
Connective Tissue Cancer
16%
Febrile Neutropenia
15%
Tumor
15%
Neoplasm
15%
Bevacizumab
14%
Squamous Cell Carcinoma
14%
Solitary Fibrous Tumor
14%
Atrophic Gastritis
14%
Neck
14%
Epithelial Cell
14%
Colorectal Carcinoma
13%
Abdominal Cancer
13%
Cell Dedifferentiation
11%
Treatment Outcome
10%
Cisplatin
10%
Tipiracil
9%
Trifluridine
9%
Salazosulfapyridine
9%
In Vitro
9%
Fusion Gene
9%
Pazopanib
8%
Intestinal Metaplasia
8%
Soft Tissue Sarcoma
8%
Spontaneous Remission
8%
Lenvatinib
8%
Diseases
8%
Bleeding
8%
Lymph Node Metastasis
8%
Ewing Sarcoma
8%
Gastrointestinal Cancer
7%
Adverse Event
7%
Hazard Ratio
7%
Malignant Neoplasm
7%
Primary Tumor
7%
Computer Assisted Tomography
7%
Nivolumab
7%
Esophageal Cancer
7%
Immunology and Microbiology
Nivolumab
43%
Cancer Cell
30%
CD44
24%
T Cell
21%
Colorectal Carcinoma
21%
Neck
21%
Cytotoxic T-Cell
18%
Squamous Cell
15%
CD4
15%
Pembrolizumab
14%
Immune Checkpoint Blockade
14%
Tertiary Lymphoid Structure
14%
Drug Resistance
11%
B Cell
10%
Immunocompetent Cell
10%
T Helper Cell
9%
Programmed Cell Death 1
9%
Sulfasalazine
9%
Microsatellite Instability
9%
CD44v Antigen
8%
Lung
8%
Imaging Mass Spectrometry
8%
Ribonucleic Acid
8%
Cell Population
8%
CD8
8%
Regulatory T Cell
7%
Colon
7%
Tumor Cell
7%
Bevacizumab
7%
T-Helper Cell
7%
Infliximab
7%
Lymphoproliferative Disorders
7%
LAG3
7%
Synovitis
7%
Alternative RNA Splicing
7%
Insulin-Like Growth Factor 1 Receptor
7%
Methylation
7%
Mucin
7%
Ascites Tumor Cell
7%
M2 Macrophages
7%
Glioma Cell
7%
Auto-immunity
7%
Cell Death
7%
Trastuzumab Deruxtecan
7%
Albumin
7%
DNA Methylation
7%
Amino Acid Transport
7%
Cell Differentiation
7%
DNA Damage
7%
Intravenous Immunoglobulin
7%